← All Sponsors
SPONSOR

Nuvation Bio Inc.

Total Trials
2
Recruiting
2
Phases
Phase 3
Conditions studied: Non Small Cell Lung CancerGliomaAstrocytoma, Grade IVIDH1-mutant GliomaAstrocytoma, IDH-Mutant, Grade 3Astrocytoma, IDH-Mutant, Grade 4Astrocytoma, IDH-Mutant, Grade 2OligodendrogliomaOligodendroglioma, IDH-Mutant and 1p/19q-Codeleted

Clinical Trials by Nuvation Bio Inc.

NCT06564324 Phase 3
Recruiting

A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients

Non Small Cell Lung Cancer
China View Trial →
NCT05303519 Phase 3
Recruiting

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

Glioma
United States, Australia, China View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology